There were a few new and some old things mentioned in the post approval session and here are a few nuggets that may be helpful for our readers to know.

With regards to CBE-0 and CBE-30 supplements, there is a new process that OGD will use.  This new process was developed to better trace these two types of supplements and to better document the actions taken in the system. However, applications holders should note that there may not be a separate approval letter that you will receive for the CBE-0 or CBE-30. OGD will issue an acknowledgement letter within the 30 day period along with the name and contact person for further inquiries. The applicant will also be notified if the supplement is not appropriate for the CBE and a change to a PAS will be made through an official letter notifying the sponsor of the change. If the supplement does qualify as a CBE-0 or CBE-30, the acknowledgement letter is the only thing you will receive. You will receive no further correspondence from OGD regarding approval status. So, the acknowledgement letter will be considered an approval action for your files. This change eliminated the need for OGD to issue a second correspondence if the supplement is accepted in one of the less burdensome categories.

Remember that for grouped supplements, it is necessary to file the change separately to each application, and supporting information should be the same for every application in the group. The FDA also notes to be sure when submitting facility change information, you must verify that the facility is in acceptable compliance status. Firms should also not respond to complete response letters where there is a compliance problem with one of the facilities in your supply chain until the facility issues have been resolved.

It looks like the FDA is ramping up to modernize and revamp the SUPAC documents based on revisions in various ICH guidance issued. There may also be some additional changes in the SUPAC documents to incorporate stakeholder input based on the FDA request for comments in the March 3, 2026, FR notice (here). Hopefully this is an effort to make the documents clearer and to accelerate change while safeguarding patients.

More to follow!